Jim Simons’s Entrada Therapeutics TRDA Stock Holding History

Jim Simons’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.55M	Sell	202,084 -50,551	-20%	-$579K	﹤0.01%	1755
2025 Q4	$2.6M	Sell	252,635 -341,665	-57%	-$2.88M	﹤0.01%	1703
2025 Q3	$3.45M	Buy	594,300 +214,800	+57%	+$1.26M	﹤0.01%	1703
2025 Q2	$2.55M	Buy	379,500 +51,015	+16%	+$410K	﹤0.01%	1961
2025 Q1	$2.97M	Buy	328,485 +162,285	+98%	+$2.02M	﹤0.01%	1751
2024 Q4	$2.87M	Buy	166,200 +72,400	+77%	+$1.31M	﹤0.01%	1807
2024 Q3	$1.5M	Buy	93,800 +49,200	+110%	+$775K	﹤0.01%	2202
2024 Q2	$636K	Buy	+44,600	New	+$634K	﹤0.01%	2583
2022 Q2	–	Sell	-11,800	Closed	-$111K	–	4579
2022 Q1	$111K	Sell	11,800 -1,773	-13%	-$19K	﹤0.01%	3774
2021 Q4	$232K	Buy	+13,573	New	+$329K	﹤0.01%	3455

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jim Simons's TRDA Position: Q1 2026 in Review

Jim Simons reduced its Entrada Therapeutics (TRDA) stake by 20% in Q1 2026, selling an estimated $579K and leaving 202,084 shares worth $2.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1755.

Jim Simons first reported a position in TRDA in Q4 2021 and has held it in 10 quarters since. The position peaked at $3.45M in Q3 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

Jim Simons held 202,084 shares of Entrada Therapeutics worth $2.55M as of Q1 2026.
Jim Simons sold 50,551 Entrada Therapeutics shares in Q1 2026, an estimated $579K.
Entrada Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1755 holding.
Jim Simons first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 10 quarters since.
Jim Simons's Entrada Therapeutics position peaked at $3.45M in Q3 2025.
120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.